microbiome

Developing a range of products to modify the human
microbiome and bring specific health benefits

RNS & Investor News

Total Voting Rights

31 July 2017

For the purposes of the Financial Conduct Authority's (FCA) Disclosure and Transparency Rules, the issued ordinary share capital of the Company comprises 78,543,318 ordinary shares of 2p each ('Ordinary Shares').

The Company does not hold any Ordinary Shares in Treasury. Therefore, the total number of Ordinary Shares carrying voting rights in the Company is 78,543,318.  Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the FCA's Disclosure and Transparency Rules.

The Company has been made aware that as a result of a typographical error on an application for admission in January 2015 sixty ordinary shares had not been admitted to trading on AIM. Application has now been made for these sixty shares to be admitted to trading on AIM which is expected to occur on or around 4 August 2017. There is no change to the issued share capital as a result of this application, which was correctly notified at the time.

 

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
www.optibiotix.com
Contact via Walbrook below
   
Cairn Financial Advisers LLP (NOMAD)
Liam Murray / Jo Turner
Tel: 020 7213 0880
   
finnCap (Broker)
Adrian Hargrave / Scott Mathieson / Kate Bannatyne (Corporate Finance)
Tony Quirke (Corporate Broking)
Tel: 020 7220 0500
   
Walbrook PR Ltd
Anna Dunphy
Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Mob: 07876 741 001

 

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

 

back to RNS & Investor News

 

Latest Tweets Twitter

top